Just listened to presentation. DP did not disclose numbers but optimistic about rising revenue from Erivedge royalties. Key will be read out in second half of 2013 on operable bcc trial. He expects it to be positive which he believes would represent a "dramatic enhancement" of Erivedge. So FDA approval and EU conditional approval of Erivedge kept CRIS from going bankrupt, but it does not appear price of stock will move upward dramatically unless there is progress on 907. I assume that the prospect of that drug going to market is 5 years away if all goes well, but given its broad application positive news along the way could cause the stock to jump.